ENTERO THERAPEUTICS INC (ENTO) Stock Price & Overview
NASDAQ:ENTO • US33749P5070
Current stock price
The current stock price of ENTO is 2.99 USD. Today ENTO is up by 5.28%. In the past month the price decreased by -32.51%. In the past year, price increased by 110.49%.
ENTO Key Statistics
- Market Cap
- 10.046M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -11.09
- Dividend Yield
- N/A
ENTO Stock Performance
ENTO Stock Chart
ENTO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ENTO. When comparing the yearly performance of all stocks, ENTO is one of the better performing stocks in the market, outperforming 95.32% of all stocks.
ENTO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ENTO. ENTO has a bad profitability rating. Also its financial health evaluation is rather negative.
ENTO Earnings
ENTO Forecast & Estimates
ENTO Groups
Sector & Classification
ENTO Financial Highlights
Over the last trailing twelve months ENTO reported a non-GAAP Earnings per Share(EPS) of -11.09. The EPS increased by 76.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.48% | ||
| ROE | -31.45% | ||
| Debt/Equity | 0.01 |
ENTO Ownership
ENTO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.82 | 364.65B | ||
| AMGN | AMGEN INC | 15.24 | 188.631B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 175.177B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.42 | 116.358B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.68 | 77.963B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.84 | 41.258B | ||
| INSM | INSMED INC | N/A | 31.039B | ||
| NTRA | NATERA INC | N/A | 28.733B | ||
| BIIB | BIOGEN INC | 11.29 | 26.917B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.55 | 23.098B | ||
| MRNA | MODERNA INC | N/A | 20.683B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 19.837B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.676B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ENTO
Company Profile
Entero Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal diseases. The company is headquartered in Boca Raton, Florida and currently employs 2 full-time employees. The company went IPO on 2016-10-11. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The firm is focused on developing the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis (CF) and chronic pancreatitis (CP) patients with exocrine pancreatic insufficiency (EPI). Adrulipase is the active pharmaceutical ingredient (API) derived from Yarrowia lipolytica, an aerobic yeast naturally found in various foods such as cheese and olive oil that is widely used as a biocatalyst in several industrial processes. The firm is developing Adrulipase for two principal therapeutic indications: children and adults affected by CF, and adult patients with CP.
Company Info
IPO: 2016-10-11
ENTERO THERAPEUTICS INC
777 Yamato Road, Suite 502
Boca Raton FLORIDA US
Employees: 2
Phone: 15615897020
ENTERO THERAPEUTICS INC / ENTO FAQ
What does ENTO do?
Entero Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal diseases. The company is headquartered in Boca Raton, Florida and currently employs 2 full-time employees. The company went IPO on 2016-10-11. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The firm is focused on developing the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis (CF) and chronic pancreatitis (CP) patients with exocrine pancreatic insufficiency (EPI). Adrulipase is the active pharmaceutical ingredient (API) derived from Yarrowia lipolytica, an aerobic yeast naturally found in various foods such as cheese and olive oil that is widely used as a biocatalyst in several industrial processes. The firm is developing Adrulipase for two principal therapeutic indications: children and adults affected by CF, and adult patients with CP.
What is the stock price of ENTERO THERAPEUTICS INC today?
The current stock price of ENTO is 2.99 USD. The price increased by 5.28% in the last trading session.
Does ENTO stock pay dividends?
ENTO does not pay a dividend.
How is the ChartMill rating for ENTERO THERAPEUTICS INC?
ENTO has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists ENTO stock?
ENTO stock is listed on the Nasdaq exchange.